Compare Quest Diagnostics Inc (DGX) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SYSCO Corporation — how do they compare? Quest Diagnostics Inc trades at $205.21 (market cap $22.80B), while SYSCO Corporation trades at $82.4 (market cap $39.62B). The key difference: SYSCO Corporation is the larger of the two by market cap, and SYSCO Corporation pays the higher dividend (2.66%). Which is the better fit depends on your goals.
| DGX | SYY | |
|---|---|---|
Market Cap | $22.80B | $39.62B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $91.16 |
52-Week Low | $166.42 | $69.30 |
Enterprise Value | $28.82B | $53.10B |
Dividend Yield | 1.67% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Sysco Corporation (SYY) trades at $83.46, down 0.44% on the day, with a bullish technical signal and positive analyst sentiment. The stock shows strong fundamentals with consistent revenue growth reaching $81.37B in 2025 and a net income margin of 2.08%. Recent earnings beat expectations in Q3 and Q4 2025, though Q1 2026 slightly missed. The company maintains solid cash flow generation and recently announced a $0.55 dividend payable in July 2026.
Sysco's outlook remains favorable with 60% analyst buy ratings and a consensus price target of $83.67, slightly above current levels. Key opportunities include sustained revenue growth and operational efficiencies, while risks involve margin pressure and competitive industry dynamics. The stock presents a balanced investment case with moderate upside potential amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
